Company intelligence / Profile preview

Arixa Pharmaceuticals

Palo Alto, California, United Statesbiospace.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The lead compound ARX‑1796, an oral prodrug of avibactam, demonstrated 60–80% absorption when administered orally in humans during a Phase 1 clinical trial. This enables the potential for the first novel oral beta-lactamase inhibitor + antibiotic combination in over three decades. The company was acquired by Pfizer to advance further development[1][2][5][6].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (oral prodrugs of beta-lactamase inhibitors)
Industry: Biotech

Drug pipeline

1 asset

ARX-1796

Phase 1

Indications: Urinary tract infections, Drug-resistant Gram-negative infections

Partnerships

Pfizer Hospital Business division acquired and continues development of lead asset[1]

Beyond the preview

Go deeper on Arixa Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arixa Pharmaceuticals.

Explore the full profile